Advocacy intelligence hub — real-time data for patient organizations
Extraneal (with 7.5% Icodextrin) Peritoneal Dialysis Solutio: FDA approved
For use as a single daily exchange for the long (8-16 hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of chronic renal failure.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Extraneal (with 7.5% Icodextrin) Peritoneal Dialysis Solutio
Baxter Healthcare Corporation
Extraneal (with 7.5% Icodextrin) Peritoneal Dialysis Solutio
(Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution)Orphan drugBaxter Healthcare Corporation
Livtencity
(maribavir)Orphan drugstandardTakeda Pharmaceuticals U.S.A., Inc.
Cytomegalovirus pUL97 Kinase Inhibitor [EPC]
12.1 Mechanism of Action LIVTENCITY is an antiviral drug against human CMV [see Microbiology (12.4) ] .
Browse all Off-periods in Parkinson disease not responding to oral treatment news →
View all Off-periods in Parkinson disease not responding to oral treatment specialists →